The research unit was established in 2016 and currently counts ten researchers. Its main research areas comprise deprescribing, with a specific focus on deprescribing in the last part of life, as well as research related to transitions of care and clinical research. Read more about it here.
The unit is represented by Carina Lundby, who, besides her deprescribing research, is the founder of the Northern European Researchers in Deprescribing (NERD) network and runs the blog section on deprescribing.org.
The research unit is an expanding entity both in terms of affiliated researchers and scientific output. Its main research areas comprise clinical pharmacy and frailty among older patients as well as cross sectional research. Read more about it here.
The unit is represented by professor, consultant, and Head of Research Jesper Ryg, who has published more than 75 peer-reviewed papers within the multiple aspects of geriatric medicine including use of medications, frailty, and end-of-life matters.
The department houses an internationally recognized pharmacoepidemiology unit that has existed for 30 years and currently comprise around 30 people, doing both methodological and applied research mainly within drug safety. Read more about it here.
The unit is represented by professor of pharmacoepidemiology Anton Pottegård, who has published more than 250 peer-reviewed papers on all aspects of medication use, primarily within registry-based research.
The department is currently expanding its activities, both with respect to the portfolio of clinical services and with respect to research activities. The research unit embraces all aspects of clinical pharmacology, from pharmacogenomics through polypharmacy to rational use of medications in everyday clinical practice. Read more about it here.
The unit is represented by professor, consultant Per Damkier, who has published more than 175 peer-reviewed papers, spanning broadly across most aspects of medication use.
The research unit embraces all aspects of primary care research including clinical trials, epidemiology, organisational research, implementation methods and research on chronic diseases. The research unit currently counts seven professors, fourteen associate professors, and >40 post docs, PhD students and support staff. Read more about it here
The unit is represented by research leader, professor Jens Søndergaard, general practitioner and clinical pharmacologist. He has published more than 250 peer-reviewed papers.
A portfolio of projects including literature reviews, qualitative studies and quantitative studies to describe patient’s, relatives’ and health care professionals’ barriers regarding deprescribing.
For older individuals reaching the last years of life, continued use of some medications may be of questionable benefit due a limited life expectancy and shifts in goals of care. In such situations, it may therefore be relevant to reduce or discontinue treatment with these medications. Despite this, a number of barriers towards deprescribing have been identified among both patients, relatives, and health care professionals.
In a series of papers, we explore attitudes towards deprescribing from the perspective of both patients, relatives, and health care professionals. We do this to get a better understanding of what may hinder as well as facilitate deprescribing, as this will help us developing interventions, tools, and strategies that may improve the uptake of deprescribing in clinical practice. We explore patient/relative and prescriber perspectives through both systematic reviews, qualitative studies, and surveys.
A primary care RCT testing a comprehensive deprescribing intervention on quality of life among patients with limited life expectancy.
Numerous deprescribing interventions have been shown to be feasible, safe, and generally effective at reducing medication use. However, the evidence of impact on patient-important outcomes, such as quality of life, is limited.
With ODIN-1, we will test whether a comprehensive and patient-centered deprescribing intervention can improve quality of life as well as other outcomes among older patients with limited life expectancy. The intervention will be focused on aligning medical treatment with patient’s preferences, and it will be carried out in collaboration between patient and general practitioner.
The trial will be initiated during the summer of 2020 and run for one year. The study is funded by the VELUX Foundation.
A portfolio of studies exploring patients’ preferences for discussing life expectancy.
A patient’s estimated life expectancy is an essential part of individual care planning in the last part of life. A careful discussion about life expectancy between patients and physicians may assist patients in making informed decisions related to e.g. medication use and deprescribing, screening needs, and personalized care. Several studies have explored patient preferences for discussing life expectancy but the results are conflicting. Further, previous research has primarily focused on the preferences of patients with cancer and to a lesser extent other patient populations where discussions about life expectancy may also be particularly relevant.
In two studies, we explore patient preferences for discussing life expectancy. In the first study, we provide a comprehensive overview of the literature on patient preferences for discussing life expectancy and, in the second study, we examine these preferences in a Danish geriatric outpatient setting.
A portfolio of register-based studies examining characteristics of and drug use patterns in the Danish nursing home population.
Admission to nursing home generally indicates an altered disease status, a certain level of frailty, and a relatively limited life expectancy, thus representing a time where treatment goals might change from preventive to symptomatic control. To ensure appropriate medication use among nursing home residents, insight into characteristics of and use of medication among nursing home residents is needed.
In a series of studies, we use the nationwide Danish health registries to examine characteristics of and drug use patterns in the Danish nursing home population.
We are hosting the 1st International Conference on Deprescribing – bringing together deprescribers from all over the world!
The 1st International Conference on Deprescribing – #ICOD2022 – will take place in Kolding, Denmark from September 5-7, 2022. The conference will be jointly hosted by the Odense Deprescribing Initiative (ODIN), the Network of Northern European Researchers in Deprescribing (NERD), the Danish Society for Clinical Pharmacology (DSKF), and the University of Southern Denmark (SDU).
The conference will feature keynote lectures, workshops, oral abstract presentations, a poster session, and social activities such as a welcome reception and a conference dinner. There will be a lot of opportunity to network and connect with other deprescribing researchers, in order to develop and strengthen collaborations. The conference will feature presentations from esteemed deprescribing researchers including Dr. Emily Reeve, Dr. Cynthia Boyd, Dr. Mike Steinman, and Dr. Barb Farrell.
For more information and to register for news regarding the conference, visit: www.conferencemanager.dk/icod2022